Drugs / DWC202404
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06682000 Background | Jan → Oct 2025 | essential hypertension | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DWC202404 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06682000 ↗ |
| Route | Oral | “\- 2 tablet, Oral, Once a day” NCT06682000 ↗ |